medigraphic.com

2000, Number 3

<< Back Next >>

Rev Med Hosp Gen Mex 2000; 63 (3)

Pergolide as adjunct therapy in Parkinson’s disease evaluated using SPES

Klein C, Zoldan J, Korczyn AD, Giladi N, Aharon-Peretz J, Rabey JM

Language: English
References: 20
Page: 156-164
PDF size: 128.90 Kb.


ABSTRACT

Thirty-two patients suffering from idiopathic Parkinson’s disease (PD) (mean age 65.3; mean disease duration 7.4 years) with motor fluctuations were enrolled in five out-patient clinics throughout Israel. After a basic clinical evaluation the patients were treated with pergolide in increasing doses as add-on therapy in an open trial, lasting three months. The clinical evaluation was performed applying the Short Parkinson’s Evaluation Scale (SPES), a new friendly score, recently created by a joint European team (Rabey et al., Clinical Neuropharmacology, 1997). During the trial 13 patients withdrew: nine due to side effects: (persistent hypotension in three; nausea and dizziness in three; constipation in one; chest pains in one and headaches in one); protocol violations in one, and lost to follow up in three. Of the 19 patients who completed the study, there was improvement in the motor scoring (according to SPES) p = 0.01, and also in activities of daily living (p = 0.001). We have thus confirmed the benefit of pergolide as add-on therapy for PD patients and advise that in view of possible side-effects the dose be carefully and gradually increased. In addition, SPES seems to be a useful tool for the clinical evaluation of new therapies for PD.


REFERENCES

  1. Rabey JM. Second generation of dopamine agonists: Pros and cons. In: Bonuccelli U, Rabey JM (eds). Old and new dopamine agonists in Parkinson’s disease. Wien, New York: Springer-Verlag, 1995; 213-224.

  2. Korczyn AD. Parkinson’s disease. In: Floyd E. Bloom, David J. Kupfer (eds). Psychopharmacology: The fourth generation of progress. New York: Raven Press Ltd., 1995; chapter 126: l479-1484.

  3. Pezzoli G, Canesi M, Pesenti A, Mariani CB. Pergolide mesylate in Parkinson’s disease treatment. J Neurol Transm Supp 1995; 45: 203-212.

  4. Lees AJ, Stern GM. Pergolide and lisuride for levodopa induced oscillations. Lancet II. 1981; 577.

  5. Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg M. Treatment of advanced Parkinson’s disease with pergolide. Neurology 1981; 12: 243-247.

  6. Goldstein M, Lieberman A, Lew J, Asano J, Rosenfeld M, Matwan. Interaction of pergolide with central dopaminergic receptors. Neurobiology 1980; 77: 3725-3728.

  7. Rabey JM, Passeltiner P, Markey K, Asano J, Goldstein M. Stimulation of pre and post synaptic dopamine receptors by an ergoline and by a partial ergoline. Brain Res 1981; 225: 347-356.

  8. Lataste X, Markstein R, Jaton AL. Dopamine agonist: An update on the model of action. In: Lieberman AN, Lataste X (eds). Parkinson’s disease: The role of dopamine agonists. New trend in clinical neurology. Carnforth, UK: Parthenon Publishing Group, 1989: l3-28.

  9. Jankovic J. Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy. Neurology 1983; 33: 500-507.

  10. Diamond SG, Markham CH. One year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson’s disease. Adv Neurol 1984; 40: 537-539.

  11. Sage JI, Duvoision RC. Pergolide therapy in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 1985; 8: 260-265.

  12. Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson’s disease. Adv Neurol 1986; 45: 551-554.

  13. Markham CH, Diamond SG. Pergolide: a double-blind trial as adjunct therapy in Parkinson’s disease. In: Fahn S et al (eds). Recent developments in Parkinson’s disease. New York: Raven Press, 1986; 331-337.

  14. OLanow CW, Alberts MJ. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson’s disease. Clin Neuropharmacol 1987; 10: 178-185.

  15. Ahlskog JE, Muenter MD. Treatment of Parkinson’s disease with pergolide: a double-blind study. Mayo Clinic Proc 1988; 63: 969-978.

  16. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, Hoehn M, Markham CH, Duvoisin R, Reinmuth O, Leonard HA, Ahlskog E, Feldman R, Hershey L, Yahr MD. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994; 9: 40-47.

  17. Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Vansauten W, Van Hilten B. Evaluation of the Short Parkinson’s Evaluation Scale: A new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clin Neuropharm 1997; 20(4): 322-337.

  18. Fahn S, Elton RL and members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent development in Parkinson’s Disease, vol. 2, Florham Park, NJ: Macmillan Health Care Information 1987: 153-164.

  19. van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RAC. Rating impairment and disability in Parkinson’s disease: Evaluation of the Unified Parkinson’s Disease Rating Scale. Mov Disord 1994; 9(1): 84-88.

  20. Guy W. Clinical Global Assessment Scale (CGI). In: ECDEU assessment manual for psychopharmacology. US Dept of Health Education and Welfare. NIHM. Rockville, MD. 1976.




2020     |     www.medigraphic.com